The Daily Toke

April 26, 2026

Trump administration officials have reclassified medical marijuana as a lower-risk drug, marking a significant federal policy shift that's already triggering state-level legislative responses. The Trump administration eased rules on certain marijuana categories, a move that comes as the Drug Enforcement Administration and other federal agencies recalibrate how they treat cannabis products. Tennessee lawmakers have already moved to capitalize on the moment, with one legislator calling for a special legislative session specifically focused on medical marijuana policy now that federal reclassification has opened new possibilities. 🚀 THIS IS COOL This reclassification acknowledges what researchers have documented for decades: medical cannabis has legitimate therapeutic applications for conditions ranging from chronic pain to PTSD, particularly among veterans who've found cannabis an alternative to opioid prescriptions that kill over 16,000 Americans annually.

The reclassification also triggered a congressional directive for federal agencies to study how state marijuana laws interact with changing federal policy. A House committee ordered relevant federal agencies to examine state-level cannabis regulations, suggesting lawmakers recognize that 50 years of Schedule I classification—maintained since Nixon's 1970 Controlled Substances Act despite his own Shafer Commission recommending decriminalization—created legal chaos that needs untangling. States have moved far ahead of federal policy, but the gridlock between state legalization and federal scheduling made it difficult for researchers, patients, and businesses to operate with clarity.

💰 MONEY MOVES The economic implications are substantial. States with established legal cannabis markets have generated billions in tax revenue and created regulated job markets, while the federal reclassification could unlock research funding and reduce barriers to interstate commerce for compliant operators. Medical marijuana legalization also typically reduces pressure on opioid markets, which has public health implications beyond just individual patient choice. When veterans and chronic pain patients have access to regulated cannabis products instead of higher-risk pharmaceutical alternatives, healthcare costs and overdose deaths both decline—though that outcome rarely gets mentioned in drug policy debates focused solely on cannabis risk rather than comparative risk.

The timing matters. Federal reclassification doesn't automatically legalize cannabis nationwide, but it signals that the three-decade narrative of cannabis as a Schedule I substance with "no medical value" has officially collapsed at the administrative level. States like Tennessee, which previously rejected medical marijuana programs, now face political and practical pressure to reconsider. Patients in those states currently have fewer legal options than patients in neighboring states, and federal acknowledgment that medical marijuana has therapeutic merit removes the policy excuse for continued state-level bans.

🤔 THINK ABOUT IT Here's the underlying tension: alcohol kills roughly 95,000 Americans every year, tobacco kills over 400,000, and prescription opioids kill roughly 16,000 annually—yet all remain legal and heavily lobbied. Cannabis has zero recorded overdose deaths in human history. It's been reclassified as lower-risk by the Trump administration. So if the stated concern is public health protection, why did cannabis stay Schedule I while these documented killers remained legal? The answer typically involves historical policy inertia, enforcement agency budgets tied to drug war spending, and political liability rather than comparative risk assessment. Federal reclassification might finally force that conversation into the open.

April 26, 2026

Pennsylvania's governor is calling Trump's move to reschedule medical marijuana from Schedule I to Schedule III "an important step" toward legalization, while neighboring states continue raking in hundreds of millions in tax revenue that the commonwealth is currently leaving on the table. Gov. Josh Shapiro's administration projects that if recreational marijuana legalization passes by July 1, Pennsylvania could generate $729 million in tax revenue—money that would flow into state coffers while competitors like New York, New Jersey, and Ohio have already captured their market share. 💰 MONEY MOVES The rescheduling decision, issued Thursday by Acting U.S. Attorney General Todd Blanche, moves medical marijuana out of the most restrictive federal classification for the first time since 1970 and delivers an immediate tax break to cannabis businesses by allowing them access to standard business deductions previously unavailable under Schedule I restrictions.

But while Pennsylvania looks forward, Missouri is moving in the opposite direction. Gov. Mike Kehoe signed legislation Thursday that will ban all intoxicating hemp-derived THC products from shelves starting November 12, eliminating a largely unregulated industry that has grown to fill the gap left by prohibition in states without legal cannabis markets. The bill aligns Missouri with a federal ban Congress approved in November, and Kehoe framed the move as child protection, noting the bipartisan vote (151 ayes, 28 nays across both chambers). However, the Missouri Hemp Trade Association painted a different picture, calling the legislation a dismantling of "an industry built by real Missourians who have operated in good faith under existing federal and state law"—an industry that generated roughly $10,000 in handwritten letters to the governor's office in just 10 days, asking him to veto the bill.

At the federal level, the White House is actively shaping the regulatory framework. On Tuesday, Vince Haley (director of the White House Domestic Policy Council) and James Braid (assistant to the president for legislative affairs) sent legislative suggestions to Rep. Andy Barr (R-KY), who has been pushing for a regulatory model rather than outright prohibition. The administration indicated support for protecting CBD access while restricting "products that pose serious health risks"—language that remains vague, given that cannabis and hemp-derived products have caused zero recorded overdose deaths. 🚀 THIS IS COOL The White House engagement suggests the administration recognizes that blanket prohibition may not be the most effective policy lever, and that creating a legitimate regulatory framework could actually serve public health better than driving the market further underground.

Rep. Mary Miller (R-IL) has filed a competing amendment that would accelerate the hemp ban to take effect immediately upon passage of the new Farm Bill, rather than waiting until November 12. This creates a three-way tension: the White House exploring regulatory frameworks, GOP lawmakers like Barr advocating for controlled legalization, and hardliners like Miller pushing for faster prohibition. Meanwhile, Barr's own amendment—which would have preserved the lawful hemp market while creating safety guardrails around synthetics and foreign-origin products—was quietly withdrawn this week without explanation. 🤔 THINK ABOUT IT One state is watching neighboring economies boom while its governor pleads with lawmakers to legalize and capture tax revenue; another state is dismantling a legal industry in the name of child safety while keeping alcohol fully legal; and the federal government is simultaneously exploring regulation, pushing prohibition, and letting different states run conflicting experiments. Which approach actually serves public health and economic fairness?

April 26, 2026

Federal hemp restrictions signed into law in November 2025 will effectively eliminate nearly all intoxicating hemp products from the U.S. market by November 12, 2026, marking the most dramatic reversal of hemp policy since the 2018 Farm Bill first legalized the plant. On November 12, President Trump signed the Continuing Appropriations Act, 2026 (P.L. 119-37), which rewrote the federal definition of hemp and imposed restrictions that industry leaders say will destroy a $28.4 billion market that employed an estimated 300,000 workers and generated roughly $1.5 billion in state tax revenue annually. The legislation replaces the 2018 Farm Bill's delta-9 THC concentration standard with a "total THC" cap—meaning any THC compound, including THCA, delta-8, delta-10, and other cannabinoids, now counts toward the limit. More significantly, finished consumer products are capped at just 0.4 milligrams of total THC per container, a threshold so restrictive that it will eliminate approximately 90 to 95 percent of currently available products, since typical hemp gummies, beverages, and vapes contain between 2.5 and 10 milligrams of THC per unit.

💰 MONEY MOVES The ban will wipe out an estimated 95% of the hemp retail market when enforcement begins in twelve months, threatening jobs across farming, extraction, manufacturing, logistics, and retail. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, stated flatly: "In effect, this is a total, all out, complete ban on hemp products in the United States." Industry participants face immediate operational decisions—many are already preparing for production reductions, inventory liquidation, or business closure. Farmers who scaled up hemp cultivation after 2018 could face canceled or restructured contracts, and equipment financing that was extended during the growth years may suddenly become difficult to maintain. State tax revenues that reached $1.5 billion annually stand to vanish, and the economic ripple effects could extend to agricultural land use across the country.

The legislation also explicitly bans synthetic or chemically converted cannabinoids like delta-8 THC, delta-10 THC, and HHC—compounds that emerged when companies realized the 2018 Farm Bill's narrow focus on delta-9 THC had created a loophole. This was the legislative response to what lawmakers called the "Farm Bill loophole," which allowed manufacturers to extract CBD from legal hemp, convert it through chemical processes into intoxicating compounds, and sell them nationwide in states where recreational cannabis remained illegal. The law preserves a carve-out for "industrial hemp" cultivated for fiber, grain, oil, and seeds, but the product restrictions are so tight that even full-spectrum CBD products—which are non-intoxicating—may fall outside the definition due to the per-container milligram limit. The FDA has been directed to publish a list of naturally occurring cannabinoids within 90 days of enactment, though enforcement details remain unclear.

The one-year transition period gives industry stakeholders time to lobby for amendments, explore state-by-state alternatives, or prepare for shutdown. 🤔 THINK ABOUT IT This ban targets hemp products with zero recorded overdose deaths in human history, while alcohol—a legal, federally unregulated substance—kills approximately 95,000 Americans annually, and prescription opioids kill more than 16,000 each year. The hemp market that existed in the gaps between federal and state law served millions of consumers in states without legal recreational or medical cannabis programs, and many of those consumers included veterans using hemp-derived THC products for PTSD, chronic pain, and anxiety. The unregulated black market that emerges if the ban is enforced could push consumers toward less transparent suppliers, while veterans and patients in non-legal states may face sharply limited access to products they rely on for wellness and symptom management.

Enforcement remains an open question. The FDA has maintained since before 2018 that adding THC to food and beverage products is illegal, yet it has largely refrained from enforcement actions against hemp-derived THC brands absent egregious violations like marketing to children or making therapeutic claims. Industry observers are uncertain whether the federal government will aggressively enforce the new restrictions or whether regulation will follow the cannabis model, with enforcement left primarily to the states. Some industry participants are already exploring federal litigation challenging the constitutionality of the restrictions, while others are positioning themselves to pivot toward compliant low-dose products, international markets, or raw hemp ingredients that fall outside consumer product definitions. The hemp industry has twelve months to adapt, reorganize, or disappear—and how that transition unfolds will significantly reshape cannabis normalization policy across America.

April 26, 2026

Researchers are diving deeper into tetrahydrocannabinol's therapeutic potential just as federal policy shifts to reflect decades of emerging science. The Department of Justice is moving to reclassify medical marijuana products from Schedule I to Schedule III, a significant acknowledgment that cannabis compounds have legitimate medical applications—even if federal law has treated them as having "no accepted medical use" for over 50 years. This reclassification won't make marijuana legal at the federal level, but it will ease research constraints and allow the cannabis industry to operate with fewer bureaucratic obstacles, opening pathways for the kind of rigorous study that's been systematically restricted since Nixon's 1970 Controlled Substances Act.

🚀 THIS IS COOL The scientific evidence supporting THC's effectiveness is strongest in areas like pain management and multiple sclerosis treatment. THC works by binding to cannabinoid receptors (CB1 and CB2) throughout the brain and nervous system, modulating pain perception, inflammation, mood, sleep, and appetite regulation through the body's endocannabinoid system. Pharmaceutical formulations like dronabinol treat chemotherapy-induced nausea and HIV/AIDS-related appetite loss, while nabiximols—a botanical extract containing both THC and CBD—is already approved in the UK and Canada for MS-related spasticity and neuropathic pain. A 2023 meta-analysis confirmed cannabis's benefit for pain management across multiple health conditions, though researchers emphasize more evidence is needed on long-term safety and optimal dosing.

The science is nuanced. While human THC overdose remains extraordinarily rare—with zero recorded deaths in history—there are legitimate side effects worth understanding. Large doses or long-term use can trigger cannabinoid hyperemesis syndrome, severe nausea and vomiting resistant to standard anti-nausea medication. Smoking or vaping THC products carries respiratory risks; edibles containing 50+ mg of THC have been linked to serious adverse effects. THC can also interact with other medications and has complex liver metabolism. Regular use for even 1-2 weeks can create dependence, and chronic heavy use may impair memory and cognition, particularly in developing brains. These are real considerations that deserve honest conversation alongside the therapeutic benefits.

🤔 THINK ABOUT IT Medical marijuana reclassification is moving forward while alcohol—which kills approximately 95,000 Americans annually—remains completely legal and socially normalized. Prescription opioids kill over 16,000 people per year in the US alone. Cannabis has never killed anyone through overdose. Yet for decades, federal policy treated THC as more dangerous than either. The scientific literature now supports cannabis for pain, MS spasticity, and chemotherapy side effects. Alcohol has no medical benefit for any condition and is a leading cause of death among teenagers. So which classification actually protects public health?

💰 MONEY MOVES Modern THC potency has shifted dramatically, creating both opportunities and challenges for the emerging market. Average THC content in marijuana samples has climbed from 3.7% in the early 1990s to over 15% by 2022, with some concentrates exceeding 80%. This potency increase changes the risk profile—especially for inexperienced users—and raises questions about product standardization, labeling accuracy, and consumer education. Meanwhile, confusion between THC and CBD continues to cause real problems; unregulated CBD products frequently contain unlabeled THC at levels sufficient to trigger workplace drug screens, as documented by cases of consumers failing tests after purchasing products marketed as non-intoxicating.

The reclassification signals that federal prohibition—maintained for over half a century despite mounting evidence of medical utility—is finally yielding to clinical reality. Researchers can now more easily study THC's potential applications for Alzheimer's disease, traumatic brain injury, sleep disorders, and a range of neurological conditions where preliminary research suggests neuroprotective and anti-inflammatory effects. The conversation has shifted from whether THC has medical value to how we responsibly harness it while managing documented risks. That shift matters, and the science will only improve when researchers have genuine access to study it.

April 26, 2026

# TEXAS CANNABIS BRIEFING

Across the country, cannabis policy is shifting in ways that reveal a widening regional divide—and Texas, notably absent from recent legalization momentum, sits on the sidelines while neighboring states rake in the revenue. Pennsylvania Gov. Josh Shapiro is positioning his state to capitalize on federal movement: after the Trump administration reclassified medical marijuana from Schedule I to Schedule III this week, Shapiro's office immediately flagged the "important step" and signaled readiness to move on adult-use legalization. 💰 MONEY MOVES The state's own projections estimate legalization by July 1 would generate $729 million in tax revenue—money Pennsylvania currently loses to neighboring states with active markets. Meanwhile, Wisconsin Democrats are making the same pitch on 4/20: Lt. Gov. candidate Mandela Barnes and Rep. Francesca Hong both highlighted that Illinois alone captured $36 million in tax revenue from Wisconsin residents in a single year. These aren't hypothetical losses anymore; they're quantified economic transfers to neighboring jurisdictions.

The federal rescheduling is real but limited. Moving medical marijuana to Schedule III removes it from the most restrictive category—where it's sat alongside heroin and LSD since Nixon's 1970 Controlled Substances Act—but it stops short of legalization and applies primarily to FDA-approved products and state-regulated medical programs. U.S. Sen. John Fetterman (D-Pa.) celebrated the move as a step toward full legalization, and governors from both parties are now using federal momentum as political cover to push state legislatures. The message is consistent: 💰 MONEY MOVES every state that hasn't legalized is hemorrhaging revenue and competitive advantage to those that have.

Not all states are moving forward. Missouri Gov. Mike Kehoe (R) signed legislation Thursday banning all intoxicating hemp THC products—including THC seltzers currently sold in bars and grocery stores—effective November 12. The bill aligns state law with a federal ban Congress approved in November and passed with bipartisan support (151-28). Kehoe framed the move around child safety, stating Missouri "needs to be a place where it's safe to be able to have your children get access to a product that doesn't include harmful intoxicants." The Missouri Hemp Trade Association fought back, collecting 10,000 handwritten letters from small-business owners and farmers asking for a veto. 🤔 THINK ABOUT IT The rhetoric around "protecting children" is worth examining: alcohol, a legal product in all 50 states, kills roughly 95,000 Americans annually and is the number-one drug-related killer of teenagers. Cannabis has never caused a recorded overdose death in human history. Yet one is Schedule I and banned in many states, while the other funds state budgets and sits on every convenience store shelf.

The Schedule III reclassification also delivers a tax break to cannabis businesses—a development that matters financially for operators in states where medical or adult-use markets are already legal. For Texas, which has only a limited medical cannabis program (Compassionate Use Program), the federal shift is backdrop without direct application. 💰 MONEY MOVES Until Texas moves on legalization or expansion, the state remains a net exporter of cannabis tax revenue to Oklahoma, Colorado, and California. The political calculus is changing in other states, but Texas Republican leadership has shown little appetite for movement on broader cannabis policy—even as Democratic-led neighbors position themselves to benefit from normalization and revenue.

What's emerging is a map of state-level cannabis economics that favors early movers. Pennsylvania, Wisconsin, and other states with Democratic governors are racing to legalize and capture what their own citizens are already spending across state lines. Missouri is tightening restrictions despite federal-level reconsideration. Texas hasn't entered the conversation at scale. The gap between what neighboring states are earning and what Texas continues to forfeit grows measurable with each quarter's tax receipts published in adjacent jurisdictions. For a state economy, that's not ideology—that's just arithmetic.